We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

4 hedge funds and large institutions have $65.6M invested in Decoy Therapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

20% less capital invested

Capital invested by funds: $81.9M → $65.6M (-$16.3M)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Primecap Management
Primecap Management
California
+$8.04M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.04M
2
Capital World Investors
Capital World Investors
California
-$4.45M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.42M
4
ACP
Acuta Capital Partners
California
-$1.1M
5
NIP
Nicholas Investment Partners
California
-$710K

DCOY Hedge Fund Activity: Q1 2016 in Review

4 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2016, worth a combined $65.6M — down 20% from $81.9M a quarter earlier.

Fund positioning in DCOY was balanced in Q1 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Primecap Management, opening a new position worth an estimated $8.04M. The largest seller was Fidelity Investments, exiting entirely with an estimated $8.04M sold.

  • 4 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $65.6M of Decoy Therapeutics stock for Q1 2016, down 20% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q1 2016 and 1 closed out, a net change of 0 holders.
  • The largest Decoy Therapeutics buyer in Q1 2016 was Primecap Management, an estimated $8.04M added.
  • The largest Decoy Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $8.04M sold.

Based on aggregated 13F filings for Q1 2016.